Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Acute Lymphoblastic Leukemia, Version 1.2019 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Brown, P. A., Wieduwilt, M., Logan, A., DeAngelo, D. J., Wang, E. S., Fathi, A., Cassaday, R. D., Litzow, M., Advani, A., Aoun, P., Bhatnagar, B., Boyer, M. W., Bryan, T., Burke, P. W., Coccia, P. F., Coutre, S. E., Jain, N., Kirby, S., Liu, A., Massaro, S., Mattison, R. J., Oluwole, O., Papadantonakis, N., Park, J., Rubnitz, J. E., Uy, G. L., Gregory, K. M., Ogba, N., Shah, B. 2019; 17 (5): 414–23

Abstract

Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapies and subsequent treatment strategies. In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment.

View details for DOI 10.6004/jnccn.2019.0024

View details for Web of Science ID 000468989400003

View details for PubMedID 31085755